Corvus Pharmaceuticals (CRVS) PT Raised to $21 at Ladenburg Thalmann
Tweet Send to a Friend
Ladenburg Thalmann analyst Aydin Huseynov raised the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $21.00 (from $12.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
